Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis

INTRODUCTION: The role of bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) has been supported by a large number of data. However, whether bevacizumab biosimilars have the same efficacy and safety as the origi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Liu, Liu, Maobai, Cao, Xueqiong, Li, Na, Zheng, Bin, Deng, Jianhao, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597053/
https://www.ncbi.nlm.nih.gov/pubmed/36312816
http://dx.doi.org/10.1177/17588359221130501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597053/
https://www.ncbi.nlm.nih.gov/pubmed/36312816
http://dx.doi.org/10.1177/17588359221130501

Ejemplares similares